Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

18
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
18
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

381
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
381
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

289
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
289
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

78
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
78

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urolithiasis and crystalluria in dogs with primary portal vein hypoplasia: a retrospective study (2010-2023).

The Journal of small animal practice·2026
Same author

Spectral broadening and compression of picosecond pulses in air using a multi-pass cell.

Optics express·2026
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Laser damage of UV hafnia-based multilayer dielectric coatings at 355  nm wavelength.

Applied optics·2025
Same author

Retrospective analysis of the incidence and clinicopathological findings associated with ammonium urate urolithiasis in dogs with congenital portosystemic shunts: 363 cases (2010-2023).

The Journal of small animal practice·2025

Related Experiment Video

Updated: Oct 8, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

6.0K

Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC

S Suppadungsuk1, W Phitakwatchara2, T Reungwetwattana3

  • 1Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.

ESMO Open
|December 25, 2021
PubMed
Summary

Magnesium supplementation before cisplatin chemotherapy significantly reduced the incidence of cisplatin-associated acute kidney disease (cis-AKD) in head and neck cancer patients. This pilot study suggests magnesium preloading is a safe and effective strategy to mitigate cisplatin nephrotoxicity.

Keywords:
acute kidney diseasecisplatin nephrotoxicitymagnesium preloading

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.6K

Related Experiment Videos

Last Updated: Oct 8, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

6.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.6K

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Cisplatin is a cornerstone chemotherapy for head and neck cancers.
  • Nephrotoxicity is a significant dose-limiting side effect of cisplatin.
  • Magnesium supplementation has shown potential in reducing cisplatin-induced kidney damage in prior studies.

Purpose of the Study:

  • To investigate the efficacy of magnesium preloading in preventing cisplatin-associated nephrotoxicity.
  • To evaluate the impact of magnesium on acute kidney injury (AKI) and acute kidney disease (AKD) in patients receiving weekly low-dose cisplatin.
  • To assess the safety and tolerability of magnesium preloading in this patient population.

Main Methods:

  • A prospective, single-blinded, randomized controlled trial was conducted.
  • 30 head and neck cancer patients were randomized into a control group (saline + KCl) and a magnesium group (saline + KCl + magnesium).
  • Patients received weekly cisplatin 40 mg/m² for 7-8 weeks, with pre-chemotherapy infusions.

Main Results:

  • The incidence of cisplatin-associated acute kidney disease (cis-AKD) was significantly lower in the magnesium group (6.7%) compared to the control group (46.7%).
  • The time to develop cis-AKD was significantly shorter in the control group.
  • Tumor response rates and survival were comparable between the groups.

Conclusions:

  • Magnesium preloading is a safe and effective strategy for reducing cis-AKD in head and neck cancer patients undergoing cisplatin chemotherapy.
  • This pilot study provides encouraging evidence that warrants confirmation in larger randomized controlled trials.
  • Magnesium supplementation represents a promising approach to mitigate cisplatin-induced nephrotoxicity.